source
- Bayer to make 'careful but aggressive' return to pharma M&A, CEO saysBayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-qu…Endpoints · 2mo ago↗ source
- Alkermes' narcolepsy Phase 3 success; Boehringer's antibody dealPlus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…Endpoints · 2mo ago↗ source
- STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and moreThe 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge